Research Studies

Elevate-PD

Enrolling

Conditions:

Criteria

Ages

18+

Cognition

Dyskinesias

any

Fluctuations

Yes

Tremor

Gait

DBS

Hallucinations

About this study

The main purpose of this study is to see how effective and safe CREXONT^®is for people with Parkinson’s disease (PD) in everyday life. CREXONT is a combination of levodopa (LD) and carbidopa (CD) used to treat PD. It was approved by the Food and Drug Administration (FDA) in August 2024. Enrolling in the Miami and Boca Raton clinics.

Learn more Back to Studies

Sustain our mission to enhance lives and outcomes through research

As we work to improve patient quality of life — for their entire lifespan — we seek partners to catapult our progress. With your philanthropic investment, we can expand the breadth and depth of our efforts in three critical areas: research, clinical care and education and training.

Support Us

Research Studies

Browse Studies

Elevate-PD

Criteria

About this study

Sustain our mission to enhance lives and outcomes through research